{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:08:41Z","timestamp":1791335321479,"version":"4.3.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Catheter ablation is a recommended rhythm control therapy after failed or intolerant antiarrhythmic drug (AAD) treatment for patients with atrial fibrillation (AF). This study evaluates clinical performance and safety of pulmonary vein isolation (PVI) using the cryoballoon (Arctic Front Advance) in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p><jats:italic>Cryo AF Global Registry<\/jats:italic> is a prospective, multi-center registry. Patients with paroxysmal AF (PAF) were treated at 10 Japanese hospitals. Efficacy was evaluated by freedom from a\u2009\u2265\u200930-s recurrence of AF\/atrial flutter (AFL)\/atrial tachycardia (AT), AF-related symptoms, and quality of life using the EQ-5D-3L questionnaire. The safety endpoint was serious device- and procedure-related adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 352 patients with PAF (65\u2009\u00b1\u200910\u00a0years of age, 36% female, 36% without prior failure of AAD). Mean duration since first diagnosis of AF was 3.0\u2009\u00b1\u20095.5\u00a0years. Serious device- and procedure-related adverse event rate was 2.6% (95% <jats:italic>CI<\/jats:italic>: 1.2\u20134.8%). Freedom from AF\/AFL\/AT was 88.5% (95% <jats:italic>CI<\/jats:italic>: 84.7\u201391.4%) at 12\u00a0months and 86.7% (95% <jats:italic>CI<\/jats:italic>: 81.1\u201390.8%) at 24\u00a0months. The number of patients with\u2009\u2265\u20091 AF symptom was significantly decreased from 88% at enrollment to 22% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) at 12-month follow-up. General quality of life using EQ-5D did not improve significantly after 12\u00a0months in the summary score. However, in the visual analog scale score, there was improvement (5.8\u2009\u00b1\u200918.4; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study demonstrates that cryoablation used for PVI is a safe and effective treatment in real-world use for patients with PAF in Japan.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10840-022-01132-0","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T12:05:34Z","timestamp":1643976334000},"page":"695-703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cryoballoon ablation for paroxysmal atrial fibrillation in Japan: 2-year safety and efficacy results from the Cryo AF Global Registry"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-0569","authenticated-orcid":false,"given":"Masaomi","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Okishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjiro","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Goya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuteru","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred J.","family":"Kueffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"issue":"8","key":"1132_CR1","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1253\/circj.CJ-16-0285","volume":"80","author":"K Okumura","year":"2016","unstructured":"Okumura K, Matsumoto K, Kobayashi Y, et al. Safety and efficacy of cryoballoon ablation for paroxysmal atrial fibrillation in Japan - results from the Japanese prospective post-market surveillance study. Circ J. 2016;80(8):1744\u20139.","journal-title":"Circ J"},{"key":"1132_CR2","doi-asserted-by":"crossref","unstructured":"Kusano K, Yamane T, Inoue K, et al. The Japanese Catheter Ablation Registry (J-AB): a prospective nationwide multicenter registry in Japan. Annual report in 2018. J Arrhythm. 2020 Oct 16;36(6):953\u2013961.","DOI":"10.1002\/joa3.12445"},{"issue":"23","key":"1132_CR3","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa1602014","volume":"374","author":"KH Kuck","year":"2016","unstructured":"Kuck KH, Brugada J, F\u00fcrnkranz A, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016;374(23):2235\u201345.","journal-title":"N Engl J Med"},{"issue":"16","key":"1132_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jacc.2012.11.064","volume":"61","author":"DL Packer","year":"2013","unstructured":"Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(16):1713\u201323.","journal-title":"J Am Coll Cardiol"},{"key":"1132_CR5","doi-asserted-by":"publisher","unstructured":"Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace. 2021 Mar 17:euab029. doi: https:\/\/doi.org\/10.1093\/europace\/euab029. Epub ahead of print","DOI":"10.1093\/europace\/euab029"},{"issue":"4","key":"1132_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2029554","volume":"384","author":"OM Wazni","year":"2021","unstructured":"Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384(4):316\u201324.","journal-title":"N Engl J Med"},{"issue":"7","key":"1132_CR7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.hrthm.2015.03.021","volume":"12","author":"W Su","year":"2015","unstructured":"Su W, Kowal R, Kowalski M, et al. Best practice guide for cryoballoon ablation in atrial fibrillation: the compilation experience of more than 3000 procedures. Heart Rhythm. 2015;12(7):1658\u201366.","journal-title":"Heart Rhythm"},{"issue":"4","key":"1132_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/hec.673","volume":"11","author":"A Tsuchiya","year":"2002","unstructured":"Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11(4):341\u201353.","journal-title":"Health Econ"},{"key":"1132_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2020.11.016","author":"S Miyazaki","year":"2021","unstructured":"Miyazaki S, Kobori A, Sasaki Y, et al. Real-World safety profile of atrial fibrillation ablation using a second-generation cryoballoon in Japan: insight from a large multicenter observational study. JACC Clinical electrophysiology. 2021. https:\/\/doi.org\/10.1016\/j.jacep.2020.11.016.","journal-title":"JACC Clinical electrophysiology"},{"issue":"9","key":"1132_CR10","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.hrthm.2018.04.021","volume":"15","author":"W Su","year":"2018","unstructured":"Su W, Aryana A, Passman R, et al. Cryoballoon best practices II: practical guide to procedural monitoring and dosing during atrial fibrillation ablation from the perspective of experienced users. Heart Rhythm. 2018;15(9):1348\u201355.","journal-title":"Heart Rhythm"},{"issue":"9","key":"1132_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.hrthm.2017.06.020","volume":"14","author":"A Aryana","year":"2017","unstructured":"Aryana A, Kenigsberg DN, Kowalski M, et al. Verification of a novel atrial fibrillation cryoablation dosing algorithm guided by time-to-pulmonary vein isolation: results from the cryo-DOSING study (cryoballoon-ablation DOSING based on the assessment of time-to-effect and pulmonary vein isolation guidance). Heart Rhythm. 2017;14(9):1319\u201325.","journal-title":"Heart Rhythm"},{"key":"1132_CR12","doi-asserted-by":"publisher","unstructured":"Knight BP, Novak PG, Sangrigoli R, et al; STOP AF PAS Investigators. Long-term outcomes after ablation for paroxysmal atrial fibrillation using the second-generation cryoballoon: final results from STOP AF post-approval study. JACC Clin Electrophysiol. 2019 Mar;5(3):306\u2013314. doi: https:\/\/doi.org\/10.1016\/j.jacep.2018.11.006.","DOI":"10.1016\/j.jacep.2018.11.006"},{"key":"1132_CR13","doi-asserted-by":"publisher","unstructured":"Kuck KH, F\u00fcrnkranz A, Chun KR,et al. FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016 Oct 7;37(38):2858\u20132865. doi: https:\/\/doi.org\/10.1093\/eurheartj\/ehw285","DOI":"10.1093\/eurheartj\/ehw285"},{"key":"1132_CR14","doi-asserted-by":"crossref","unstructured":"Knight BP, Novak PG, Sangrigoli R, et al.; STOP AF PAS Investigators. Long-term outcomes after ablation for paroxysmal atrial fibrillation using the second-generation cryoballoon: final results from STOP AF post-approval study. JACC Clin Electrophysiol. 2019; 5(3): 306\u2013314.","DOI":"10.1016\/j.jacep.2018.11.006"},{"issue":"2","key":"1132_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jacep.2016.07.002","volume":"3","author":"KRJ Chun","year":"2017","unstructured":"Chun KRJ, Perrotta L, Bordignon S, et al. Complications in catheter ablation of atrial fibrillation in 3,000 consecutive procedures: balloon versus radiofrequency current ablation. JACC Clin Electrophysiol. 2017;3(2):154\u201361.","journal-title":"JACC Clin Electrophysiol"},{"issue":"9","key":"1132_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/europace\/euz155","volume":"21","author":"E Hoffmann","year":"2019","unstructured":"Hoffmann E, Straube F, Wegscheider K, et al. Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation. Europace. 2019;21(9):1313\u201324.","journal-title":"Europace"},{"key":"1132_CR17","doi-asserted-by":"publisher","unstructured":"Hindricks G, Potpara T, Dag\u00a0res N, et al. ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 Aug 29:ehaa612. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612. Epub ahead of print","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"1132_CR18","doi-asserted-by":"publisher","unstructured":"January CT, Wann LS, Alpert JS, et al; American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1\u201376. doi: https:\/\/doi.org\/10.1016\/j.jacc.2014.03.022. Epub 2014 Mar 28. Erratum in: J Am Coll Cardiol. 2014 Dec 2;64(21):2305\u20137.","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"1132_CR19","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","volume":"14","author":"H Calkins","year":"2017","unstructured":"Calkins H, Hindricks G, Cappato R, et al. 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14:e275\u2013444.","journal-title":"Heart Rhythm"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-022-01132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-022-01132-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-022-01132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T04:09:10Z","timestamp":1663042150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-022-01132-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1007\/s10840-022-01132-0","relation":{},"ISSN":["1383-875X","1572-8595"],"issn-type":[{"value":"1383-875X","type":"print"},{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Kimura received honoraria from Medtronic Japan; Bristol Myers Squibb, Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., FUKUDA DENSHI CO., LTD., Boston Scientific, Abbott Medical Japan LLC., JAPAN LIFELINE Co., Ltd.; Toray Industries, Inc.; Johnson and Johnson; A. Kobori received honoraria from Medtronic Japan; J. Nitta received honoraria from Medtronic Japan; K. Hirao has no financial interests; S. Shizuta received honoraria from Bristol Myers Squibb, Pfizer Japan Inc., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, Medtronic Japan, FUKUDA DENSHI CO., LTD., Boston Scientific, Abbott Medical Japan LLC., JAPAN LIFELINE Co., Ltd.; T. Kurita received honoraria from Bayer Yakuhin, Ltd., BIOTRONIK Japan, Inc, Bristol-Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim Japan, Inc, Medtronic Japan Co., Ltd, Abbott Medical Japan Co., Ltd, Boston Scientific Japan Co., Ltd., TOA EIYO LTD; K. Okishige has no financial interests; K. Kumagai received honoraria from Medtronic Japan, NIHON KOHDEN, Japan Lifeline; J. Koyama has no financial interests; K. Hiroshima has no financial interests; O. Inaba has no financial interests; M. Goya received honoraria from Bayer Yakuhin, Ltd., Abbott Medical, Japan Lifeline, Medtronic Japan, Cook Medical;Y. Yamauchi has no financial interests; K. Okumura received honoraria from Johnson and Johnson and Medtronic; F. Kueffer and D. Becker are employed by Medtronic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}